Updated Safety Advice
Australia’s medicines regulator, the TGA, has updated warnings for popular GLP-1 medicines such as Ozempic, Wegovy, Saxenda, Trulicity and Mounjaro. These drugs help control appetite and are widely used for weight loss, especially by women.
Why the Warning Changed
The TGA reviewed reports of depression and suicidal thoughts in some people taking these medicines. There is no clear evidence the drugs cause these feelings, but the regulator wants patients to be aware and have consistent information across all brands.
What to Look Out For
Speak to your doctor if you notice:
- New or worsening depression
- Anxiety or mood changes
- Any thoughts of self-harm
Mental health can shift for many reasons, including weight changes and stress, so it’s important not to ignore these signs.
Important Advice for Mounjaro Users
The TGA also updated guidance for Mounjaro (tirzepatide), warning it may reduce the effectiveness of the pill when starting or increasing the dose. Women are advised to use non-oral contraception or add a barrier method for four weeks after each dose change.
If You’re Concerned
GLP-1 medications shouldn’t be used during pregnancy. If you have worries about side effects or mood changes, check in with your GP.
